scholarly journals Treatment of children with lesions of the gastroduodenal region using peptide bioregulators

2015 ◽  
Vol 2 (2) ◽  
pp. 44-51
Author(s):  
N.M. Shcherbak
Keyword(s):  
Peptide Bioregulators

The influence of peptide bioregulators on the structural and functional specific of face skin in elderly women

2021 ◽  
Vol 19 (4) ◽  
pp. 42-46
Author(s):  
Natalia Vladimirovna Fridman ◽  
Natalia Sergeevna Linkova ◽  
Ludmila Vasil’evna Bojko ◽  
Maka Alexandrovna Kacheli
Keyword(s):  
Elderly Women ◽  
Peptide Bioregulators

scholarly journals Prospects for using peptide bioregulators for prevention and treatment of age-associated diseases of the musculoskeletal system (review of experimental data)

2019 ◽  
pp. 13-24
Author(s):  
Г.А. Рыжак ◽  
И.Г. Попович ◽  
В.Х. Хавинсон
Keyword(s):  
Musculoskeletal System ◽  
Musculoskeletal Diseases ◽  
Experimental Studies ◽  
Osteoporosis Treatment ◽  
The Elderly ◽  
Cartilage Tissue ◽  
Peptide Bioregulators ◽  
Age Related ◽  
Prevention And Treatment ◽  
And Cartilage

Увеличение продолжительности жизни человека, наблюдаемое во всем мире, требует особого внимания к возрастным изменениям, которые влияют на качество жизни. Остеоартроз и остеопороз входят в список основных заболеваний, которые приводят к ухудшению здоровья, изменению образа жизни и в конечном итоге, к инвалидности. Несмотря на то, что современные методы, применяемые для лечения как остеоартроза, так и остеопороза достаточно широки, разработка новых препаратов для лечения этих заболеваний является весьма актуальной. Среди таких препаратов особое внимание привлекают пептидные биорегуляторы, которые обладают геропротекторным эффектом, а также оказывают профилактическое действие при различных патологических состояниях организма. Одним из таких средств является пептидный препарат Хондролюкс®, который может быть рекомендован для профилактики заболеваний, связанных с изменениями хрящевой и костной тканей. Musculoskeletal diseases are most common in the elderly. The associated physical pain and limited ability to move impair quality of life and lead to disability in older patients. Among musculoskeletal diseases, osteoarthritis and osteoporosis are the most common. Osteoarthritis is a disease associated with age-related changes in the cartilage tissue. Osteoporosis, primarily postmenopausal, is characterized by decreased bone density. The similarity of these diseases is due to the fact that they both develop over a long time and are characteristic of older people. With age, both bone and cartilage tissues tend to lose their structure due to deterioration of metabolic processes. Therefore, it is important to maintain the musculoskeletal system as long as possible and focus on prevention of osteoarthritis and osteoporosis. Treatment of such diseases is associated with substantial economic costs; therefore, development of new, efficient and safe methods, which would qualitatively change the structural and functional state of bone and cartilage tissues, is highly relevant. Experimental studies showed that a new peptide drug, Chondrolux®, can be recommended for prevention and treatment of diseases associated with degenerative and dystrophic changes in the cartilage and bone tissues.

scholarly journals Cryostructuring of Polymeric Systems. 57. Spongy Wide-Porous Cryogels Based on the Proteins of Blood Serum: Preparation, Properties and Application as the Carriers of Peptide Bioregulators

Gels ◽  
2020 ◽  
Vol 6 (4) ◽  
pp. 50
Author(s):  
Egor V. Sidorskii ◽  
Mikhail S. Krasnov ◽  
Viktoria P. Yamskova ◽  
Vladimir I. Lozinsky
Keyword(s):  
Blood Serum ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Freezing Temperature ◽  
Polymeric Systems ◽  
Peptide Bioregulators ◽  
Biological Target ◽  
Pleurodeles Waltl ◽  
Average Size

Wide-pore proteinaceous freeze–thaw spongy gels were synthesized via the cryotropic gelation technique using the bovine blood serum or its diluted solutions as the protein-containing precursors. The feed systems also included the denaturant (urea) and the thiol-reductant (cysteine). The gel-fraction yield decreased and the swelling degree of the walls of macropores in such heterophase matrices increased with decreasing the initial protein concentration. The optimum freezing temperature was found to be within a rather narrow range from −15 to −20 °C. In this case, the average size of the macropores in the resultant cryogels was 90–110 μm. The suitability of such soft wide-pore gel materials for the application as the carriers of peptide bioregulators was demonstrated in the in vitro experiments, when the posterior segments of the Pleurodeles waltl adult newts’ eyes were used as a model biological target. It was shown that a statistically reliable protective effect on the state of the sclera, vascular membrane and retinal pigment epithelium, as well as on the viability of fibroblasts, was inherent in the proteinaceous cryogels loaded with the peptide bioregulator (Viophtan-5™) isolated from the bovine eye sclera.

Pineal peptides and their role in ageing

2017 ◽  
pp. 12-19
Author(s):  
В.Х. Хавинсон ◽  
И.Г. Попович
Keyword(s):  
New Technologies ◽  
Malignant Tumors ◽  
Relevant Issue ◽  
Modern Biology ◽  
Period Analysis ◽  
Peptide Complex ◽  
Peptide Bioregulators ◽  
Age Related ◽  
Pineal Peptides

Актуальной проблемой биологии и медицины является разработка новых технологий, применение которых способно замедлять процесс преждевременного старения и развитие возраст-ассоциированных заболеваний. Одним из важных направлений является изучение эффективности геропротекторных препаратов, препятствующих процессу старения и увеличивающих среднюю продолжительность жизни. Среди таких препаратов в настоящее время большое внимание привлекают пептидные биорегуляторы. Многолетние научные исследования показали, что особенно эффективными оказались лекарственный препарат эпиталамин (комплекс пептидов, выделенных из эпифиза мозга животных) и тетрапептид эпиталон (который содержится в этом комплексе). Введение указанных препаратов животным разных видов достоверно увеличивало среднюю и максимальную продолжительность жизни и уменьшало частоту возникновения спонтанных и индуцированных канцерогенами злокачественных опухолей. Клиническое изучение эпиталамина свидетельствовало об улучшении основных физиологических показателей у пациентов пожилого и старческого возраста и привело к снижению смертности в течение 15-летнего периода наблюдений. Анализ механизмов действия препаратов эпифиза в различных экспериментах показал возможность пептидергической эпигенетической регуляции экспрессии генов и синтеза белков у эукариот. Development of new technologies aimed at prevention of early ageing and age-related diseases is a relevant issue of modern biology and medicine. Studying efficacy of geroprotective medicines, which hamper ageing and increase the average lifespan, has become a leading line of research. At present, peptide bioregulators hold a special place among such medicines. Multi-year studies have demonstrated a remarkable efficacy of Epitalamin (peptide complex isolated from animal pineal gland) and a tetrapeptide Epitalon (a part of this peptide complex). Administration of these peptide drugs to animals significantly prolonged the average and maximal lifespan and reduced the incidence of spontaneous and carcinogen-induced malignant tumors. Clinical studies of Epitalamin have demonstrated physiological improvement and decreased mortality rate in elderly and senile patients during a 15-year follow-up period. Analysis of mechanisms underlying the effect of pineal peptides in various experiments showed a possibility of peptidergic regulation for gene expression and protein synthesis in eukaryotes.

NEUROPROTECTIVE EFFECTS OF PEPTIDES

2020 ◽  
pp. 299-306
Author(s):  
Е. С. Миронова ◽  
Н. С. Линькова ◽  
И. Г. Попович ◽  
Л. С. Козина ◽  
В. Х. Хавинсон
Keyword(s):  
Nervous System ◽  
Neurodegenerative Diseases ◽  
Physiological Activity ◽  
Positive Outcomes ◽  
Age Group ◽  
Average Life ◽  
Average Life Expectancy ◽  
Neuroprotective Effects ◽  
Peptide Bioregulators ◽  
The Moment

Нейродегенеративные заболевания представляют собой гетерогенную группу патологии нервной системы и встречаются преимущественно у людей старшей возрастной группы. Частота встречаемости нейродегенеративных заболеваний непрерывно растет в связи с увеличением средней продолжительности жизни населения. В настоящее время лечение нейродегенеративных заболеваний является малоэффективным. Большинство применяемых препаратов действует лишь симптоматически. В обзоре проанализированы данные и приведены сведения о перспективности применения пептидных биорегуляторов в качестве нейропротекторов, обладающих высокой физиологической активностью и низкой иммуногенностью. Neurodegenerative diseases are a heterogeneous group of nervous system pathologies. They are found mainly in people of an older age group. The incidence of neurodegenerative diseases is continuously growing due to an increase in the average life expectancy of the population. At the moment, there are no effective and safe treatments for neurodegenerative diseases, which are most often diagnosed at the stage of decompensation, when therapy is ineffective and does not bring positive outcomes. Most of the currently used drugs act only symptomatically. The review provides analyzed data and information about the prospects of using peptide bioregulators as neuroprotectors with high physiological activity and low immunogenicity.

Application of peptide bioregulators in case of physical excretion

2017 ◽  
Vol 1 ◽  
pp. 53-59
Author(s):  
T. V. Potupchik ◽  
◽  
О. F. Veselova ◽  
L. S. Evert ◽  
I.V. Gatskikh ◽  
...  
Keyword(s):  
Peptide Bioregulators

Peptide bioregulators inhibit apoptosis

2000 ◽  
Vol 130 (6) ◽  
pp. 1175-1176 ◽  
Author(s):  
V. Kh. Khavinson ◽  
I. M. Kvetnoii
Keyword(s):  
Peptide Bioregulators

Prediction of early response to liraglutide therapy in patients with obesity

2020 ◽  
Vol 17 (1) ◽  
pp. 3-12
Author(s):  
Oksana V. Logvinova ◽  
Ekaterina A. Troshina
Keyword(s):  
Physical Activity ◽  
Mathematical Model ◽  
Body Weight ◽  
Prognostic Factors ◽  
Early Response ◽  
Initial Body Weight ◽  
Endogenous Peptide ◽  
Peptide Bioregulators ◽  
Complex Therapy ◽  
Clinically Significant

BACKGROUND: The main goal of treating obesity is to reduce the risk of developing its complications and comorbid diseases, which requires a steady decrease in body weight by at least 510%. In Russia in 2016, the list of drugs for the treatment of obesity was supplemented by a glucagon-like peptide 1 receptor agonist (GLP-1) liraglutide . There is evidence that about one third of patients do not achieve a clinically significant decrease in body weight during treatment with liraglutide, while the factors that predict the so-called early response to treatment are currently unknown. AIM: To identify prognostic factors of an early response to complex therapy of exogenously constitutional obesity, including agonist of GLP-1 receptors liraglutide, and to evaluate the effect of this therapy on the dynamics of levels of endogenous peptide bioregulators of eating behavior (IB). MATERIALS AND METHODS: The study included 42 patients with exogenously constitutional obesity, which were divided into 2 groups, comparable by sex, age and body mass index (BMI). The first group (n=22) received treatment recommendations for the correction of nutrition and physical activity, as well as liraglutide 3.0 mg for 3 months. The second group (n=20) received only recommendations for the correction of nutrition and physical activity. At the start and after 3 months, anthropometric characteristics and laboratory parameters were evaluated in all patients, including the levels of endogenous peptide bioregulators of IB (leptin, ghrelin, obestatin and GLP-1), their dynamics was compared between groups. Depending on the therapeutic effect, the 1st group was divided into two subgroups: those who achieved (n = 14) and did not achieve (n = 8) a clinically significant decrease in body weight. In both subgroups, baseline characteristics were analyzed as possible prognostic factors for the effectiveness of complex therapy. RESULTS: To predict an early response to complex therapy, including liraglutide, a mathematical model has been developed that is implemented as a calculator in MS Excel and contains a combination of initial body weight and fasting plasma ghrelin. The dynamics of body weight and BMI in the group of complex therapy was statistically significantly higher than that in the group of isolated lifestyle modifications (ILM). CONCLUSIONS: The proportion of individuals with an early response to 3.0 mg liraglutide therapy is comparable to that of data from randomized clinical trials. The mathematical model, which includes a combination of initial body weight and plasma ghrelin, allows predicting the likelihood of a clinically significant decrease in body weight after 3 months of using liraglutide 3.0 mg in combination with ILM with a sensitivity of 86% [65%; 97%] and prognostic value of a positive result of 80% [60%; 95%].

Sign in / Sign up

Export Citation Format

Share Document